RxDoctor Payments Data

Pardeep Kumar, MD

Internal Medicine · Terre Haute, INNPI 1336251354

Payments from drug & device makers

$12,983in general payments, 2019–2025

Across 830 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • AbbVie$1K
  • Novartis$903
  • Corcept Therapeutics$895
  • plus $6K from 53 others

What the payments were for

  • Food & beverage$12,85899%
  • Education$1251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk107$1,413
AstraZeneca(2 entities)75$1,229
Lilly USA, LLC90$1,162
AbbVie(2 entities)64$1,053
Novartis52$903
Corcept Therapeutics49$895
Amgen47$756
Pfizer46$670
GSK44$482
Sanofi-aventis U.S. LLC22$310
Revance Therapeutics, Inc.2$283
Bayer15$271
Boehringer Ingelheim17$262
Johnson & Johnson13$234
Takeda Pharmaceuticals U.S.A., Inc.14$232
Merck17$223
Mylan Specialty L.p.11$181
Astellas Pharma US Inc9$174
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$168
Phathom Pharmaceuticals, Inc.7$155
Abbott9$142
Biohaven Pharmaceutical Holding Company Ltd.11$131
Kowa Pharmaceuticals America, Inc.9$118
Exact Sciences7$117
E.r. Squibb & Sons, L.L.C.4$90
Dexcom, Inc.4$87
Azurity Pharmaceuticals, Inc.4$82
Scilex Pharmaceuticals Inc.5$79
Amarin Pharma, Inc.4$63
Lundbeck LLC3$62
Neurelis, Inc.2$61
Axsome Therapeutics, Inc.3$60
Bristol Myers Squibb3$57
Eisai Inc.4$55
Idorsia Pharmaceuticals US Inc3$55
Currax Pharmaceuticals LLC4$54
Teva Pharmaceuticals USA, Inc.4$54
Xeris Pharmaceuticals, Inc.3$51
Mannkind Corporation3$45
Ultragenyx Pharmaceutical Inc.2$44
Seqirus USA Inc2$34
Esperion Therapeutics, Inc.2$32
Antares Pharma, Inc.2$32
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$31
Arbor Pharmaceuticals, Inc.2$29
Amneal Pharmaceuticals LLC2$29
Radius Health, Inc.2$28
Duchesnay USA Incorporated2$28
Axonics, Inc.1$21
Alnylam Pharmaceuticals Inc.1$21
ANI Pharmaceuticals, Inc.1$19
Aimmune Therapeutics, Inc.1$18
Avvisto Therapeutics, LLC1$16
Halozyme Inc1$15
IBSA Pharma Inc.1$14
Ardelyx, Inc.1$14
Regeneron Healthcare Solutions, Inc.1$12
Almatica Pharma LLC1$12
Biohaven Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,983 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$96,655
Medicare patients
220
Services billed
1,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide257$272,631
OzempicSemaglutide192$192,723
EliquisApixaban146$82,630
JardianceEmpagliflozin103$64,519
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$43,211
TradjentaLinagliptin56$39,897
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$25,873
TrulicityDulaglutide21$25,116
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$22,405
Soliqua 100-33Insulin Glargine/Lixisenatide17$17,615
XareltoRivaroxaban16$15,749
Janumet XrSitagliptin Phos/Metformin Hcl19$14,965
Aimovig AutoinjectorErenumab-Aooe13$11,567
Tresiba Flextouch U-200Insulin Degludec16$10,763
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$9,372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,162$297,747278 claims
Novo NordiskOzempic$1,413$192,723192 claims
Boehringer IngelheimJardiance, Tradjenta$262$104,416159 claims
PfizerEliquis$670$82,630146 claims
GSKTrelegy Ellipta, Anoro Ellipta$482$48,44975 claims
MerckJanumet Xr, Janumet, Januvia$223$31,02052 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,229$25,14746 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$310$17,61517 claims
Johnson & JohnsonXarelto$234$15,74916 claims
AbbVieLinzess$1,053$7,50714 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$29$1,622227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →